Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Colice

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
BMC Pulmonary Medicine|July 19, 2019
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthmaMattis Gottlow, David J Svensson, Ilya Lipkovich, et al.
Journal of Asthma and Allergy|June 10, 2022
Targeting TSLP in AsthmaJane R Parnes, Nestor A Molfino, Gene Colice, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2016
Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma CohortPatrick C Souverein, Ellen S Koster, Gene Colice, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial AllergyJonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trialsReynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, et al.
American Journal of Respiratory and Critical Care Medicine|July 2, 2016
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe AsthmaChristopher E Brightling, Lars H Nordenmark, Meena Jain, et al.
Drug Safety|January 17, 2019
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled AsthmaMats Carlsson, Martin Braddock, Yuling Li, et al.
Journal of Clinical Pharmacology|April 18, 2024
Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled AsthmaYanan Zheng, Lubna Abuqayyas, Angelica Quartino, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 29, 2015
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthmaTrung N Tran, Robert S Zeiger, Stephen P Peters, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 16, 2022
One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI studyMasaharu Shinkai, Motohiro Ebisawa, Yasushi Fukushima, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
BMC Pulmonary Medicine|July 19, 2019
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthmaMattis Gottlow, David J Svensson, Ilya Lipkovich, et al.
Journal of Asthma and Allergy|June 10, 2022
Targeting TSLP in AsthmaJane R Parnes, Nestor A Molfino, Gene Colice, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2016
Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma CohortPatrick C Souverein, Ellen S Koster, Gene Colice, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial AllergyJonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trialsReynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, et al.
American Journal of Respiratory and Critical Care Medicine|July 2, 2016
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe AsthmaChristopher E Brightling, Lars H Nordenmark, Meena Jain, et al.
Drug Safety|January 17, 2019
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled AsthmaMats Carlsson, Martin Braddock, Yuling Li, et al.
Journal of Clinical Pharmacology|April 18, 2024
Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled AsthmaYanan Zheng, Lubna Abuqayyas, Angelica Quartino, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 29, 2015
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthmaTrung N Tran, Robert S Zeiger, Stephen P Peters, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 16, 2022
One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI studyMasaharu Shinkai, Motohiro Ebisawa, Yasushi Fukushima, et al.
Pageof 7